Suppr超能文献

探索与乳腺癌紫杉烷耐药相关的特定miRNA-mRNA轴

Exploring Specific miRNA-mRNA Axes With Relationship to Taxanes-Resistance in Breast Cancer.

作者信息

Chen Danni, Bao Chang, Zhao Feng, Yu Haogang, Zhong Guansheng, Xu Liang, Yan Senxiang

机构信息

Department of Radiation Oncology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.

Program of Innovative Cancer Therapeutics, Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.

出版信息

Front Oncol. 2020 Aug 21;10:1397. doi: 10.3389/fonc.2020.01397. eCollection 2020.

Abstract

Breast cancer is the most prevalent type of malignancy in women worldwide. Taxanes (paclitaxel and docetaxel) are widely applied as first-line chemotherapeutic agents, while the therapeutic effect is seriously limited by the development of drug resistance. In the present study, we screened out several miRNAs dysregulated in taxanes-resistant breast cancer samples and confirmed that two miRNAs (miR-335-5p and let-7c-5p) played a major role in cell proliferation, apoptosis, and chemo-resistance. In addition, the weighted gene co-expression network analysis (WGCNA) for potential target genes of miR-335-5p and let-7c-5p identified three hub genes (CXCL9, CCR7, and SOCS1) with a positive relationship to taxanes-sensitivity. Further, target relationships between miR-335-5p and CXCL9, let-7c-5p and CCR7/SOCS1 were confirmed by dual-luciferase reporter assays. Importantly, the regulatory functions of CXCL9, CCR7, and SOCS1 on proliferation and chemoresistance were validated. In conclusion, our study shed light on clinical theragnostic relationships between miR-335-5p/CXCL9, let-7c-5p/CCR7/SOCS1 axes, and taxanes-resistance in breast cancer.

摘要

乳腺癌是全球女性中最常见的恶性肿瘤类型。紫杉烷类(紫杉醇和多西他赛)作为一线化疗药物被广泛应用,但其治疗效果受到耐药性发展的严重限制。在本研究中,我们筛选出了几种在紫杉烷耐药乳腺癌样本中表达失调的miRNA,并证实了两种miRNA(miR-335-5p和let-7c-5p)在细胞增殖、凋亡和化疗耐药中起主要作用。此外,对miR-335-5p和let-7c-5p的潜在靶基因进行加权基因共表达网络分析(WGCNA),确定了三个与紫杉烷敏感性呈正相关的枢纽基因(CXCL9、CCR7和SOCS1)。进一步通过双荧光素酶报告基因检测证实了miR-335-5p与CXCL9、let-7c-5p与CCR7/SOCS1之间的靶向关系。重要的是,验证了CXCL9、CCR7和SOCS1对增殖和化疗耐药的调节功能。总之,我们揭示了miR-335-5p/CXCL9、let-7c-5p/CCR7/SOCS1轴与乳腺癌紫杉烷耐药之间的临床诊疗关系。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bba8/7473300/4f75f490f2e5/fonc-10-01397-g0001.jpg

相似文献

1
Exploring Specific miRNA-mRNA Axes With Relationship to Taxanes-Resistance in Breast Cancer.
Front Oncol. 2020 Aug 21;10:1397. doi: 10.3389/fonc.2020.01397. eCollection 2020.
2
Cytological effects of honokiol treatment and its potential mechanism of action in non-small cell lung cancer.
Biomed Pharmacother. 2019 Sep;117:109058. doi: 10.1016/j.biopha.2019.109058. Epub 2019 Jun 5.
3
MicroRNAs as possible indicators of drug sensitivity in breast cancer cell lines.
PLoS One. 2019 May 7;14(5):e0216400. doi: 10.1371/journal.pone.0216400. eCollection 2019.
4
Withaferin A mediated changes of miRNA expression in breast cancer-derived mammospheres.
Mol Carcinog. 2022 Sep;61(9):876-889. doi: 10.1002/mc.23440. Epub 2022 Jun 30.
8
The Long Non-coding RNA MEG3/miR-let-7c-5p Axis Regulates Ethanol-Induced Hepatic Steatosis and Apoptosis by Targeting NLRC5.
Front Pharmacol. 2018 Apr 10;9:302. doi: 10.3389/fphar.2018.00302. eCollection 2018.
9
Meta-microRNA Biomarker Signatures to Classify Breast Cancer Subtypes.
OMICS. 2018 Nov;22(11):709-716. doi: 10.1089/omi.2018.0157. Epub 2018 Nov 2.
10

引用本文的文献

2
PU.1 regulation of type 1 dendritic cell function via NF-κB pathway in inhibition of non-small cell lung cancer progression.
J Pharm Anal. 2025 Jul;15(7):101154. doi: 10.1016/j.jpha.2024.101154. Epub 2024 Nov 22.
8
Broadening the Horizons of RNA Delivery Strategies in Cancer Therapy.
Bioengineering (Basel). 2022 Oct 19;9(10):576. doi: 10.3390/bioengineering9100576.
9
Breast cancer: molecular mechanisms of underlying resistance and therapeutic approaches.
Am J Cancer Res. 2022 Jul 15;12(7):2920-2949. eCollection 2022.

本文引用的文献

1
Cancer statistics, 2020.
CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8.
2
Altered expression of miR-181 affects cell fate and targets drug resistance-related mechanisms.
Mol Aspects Med. 2019 Dec;70:90-105. doi: 10.1016/j.mam.2019.10.007. Epub 2019 Nov 6.
3
Distinct methylation levels of mature microRNAs in gastrointestinal cancers.
Nat Commun. 2019 Aug 29;10(1):3888. doi: 10.1038/s41467-019-11826-1.
6
MicroRNAs: Turning the Tide in Testicular Cancer.
Eur Urol. 2019 Nov;76(5):541-542. doi: 10.1016/j.eururo.2019.06.010. Epub 2019 Jun 21.
7
CXCR3-CXCL9: It's All in the Tumor.
Immunity. 2019 Jun 18;50(6):1347-1349. doi: 10.1016/j.immuni.2019.05.013.
9
Accumulation of Circulating CCR7 Natural Killer Cells Marks Melanoma Evolution and Reveals a CCL19-Dependent Metastatic Pathway.
Cancer Immunol Res. 2019 May;7(5):841-852. doi: 10.1158/2326-6066.CIR-18-0651. Epub 2019 Apr 2.
10
Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancer.
Nat Commun. 2019 Mar 20;10(1):1295. doi: 10.1038/s41467-019-09312-9.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验